Work

A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps1118

Authors: Ana Christina Garrido-Castro, William Thomas Barry, Tiffany A. Traina, Robert Wesolowski, Nadine M. Tung, Tanya Keenan, Eliezer Mendel Van Allen, Nancy U. Lin, Eric P. Winer, Ian E. Krop, Sara M. Tolaney

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2806300278

Cites:

Cited by: 4

Related to: 10